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Abstract Tumor progression depends on tumor milieu,
which influences neovasculature formation and immuno-
suppression. Combining immunotherapy with antiangiogenic/
antivascular therapy might be an effective therapeutic ap-
proach. The aim of our study was to elaborate an anticancer
therapeutic strategy based on the induction of immune re-
sponse which leads to polarization of tumor milieu. To
achieve this, we developed a tumor cell-based vaccine.
CAMEL peptide was used as a B16-F10 cell death-inducing
agent. The lysates were used as a vaccine to immunize mice
bearing B16-F10 melanoma tumors. To further improve the
therapeutic effect of the vaccine, we combined it with in-
terleukin (IL)-12 gene therapy. IL-12, a cytokine with
antiangiogenic properties, activates nonspecific and specific
immune responses. We observed that combined therapy is
significantly more effective (as compared with mono-
therapies) in inhibiting tumor growth. Furthermore, the
tested combination polarizes the tumor microenvironment,
which results in a switch from a proangiogenic/immuno-
suppressive to an antiangiogenic/immunostimulatory one.
The switch manifests itself as a decreased number of tumor
blood vessels, increased levels of tumor-infiltrating CD4?,
CD8? and NK cells, as well as lower level of suppressor
lymphocytes (Treg). Our results suggest that polarizing
tumor milieu by such combined therapy does inhibit tumor
growth and seems to be a promising therapeutic strategy.
Keywords Tumor cell-based vaccine  CAMEL 
IL-12  Combined anti-tumor therapy 
Polarization of tumor microenvironment
Introduction
Tumor microenvironment participates in two strictly re-
lated processes crucial for tumor progression: formation of
tumor blood vessels and presence of immunosuppression
milieu, which enables cancer cells to escape from immune
surveillance (Huang et al. 2013; Szala et al. 2010). This is
because the cells that contribute to tumor microenviron-
ment formation release proangiogenic agents which also
act as immunosuppression stimulants (Facciabene et al.
2012; Szala et al. 2010; Tartour et al. 2011; Terme et al.
2012). Angiogenesis is critical for tumor development as
tumors have to establish a blood supply to progress
(Carmeliet and Jain 2011; Stockmann et al. 2014). Tumor
microenvironment is regulated by numerous factors and
processes (Hanahan and Coussens 2012; Swartz et al.
2012), as well as by immune system cells (e.g. T lym-
phocytes, dendritic cells (DCs), NK cells, or macrophages)
(Ostrand-Rosenberg 2008; Shurin et al. 2012). These cells
stimulate tumor growth by releasing proangiogenic and
immunosuppressive factors (Tartour et al. 2011). There-
fore, it appears reasonable to combine immunotherapy with
therapies directed against tumor blood vessels (Huang et al.
2013; Szala et al. 2010). Certain drugs [e.g., anti-VEGFR2
monoclonal antibody (Li et al. 2006), sunitinib (Ozao-
Choy et al. 2009)] destroy tumor blood vessels and trigger
immune response by increasing the levels of CD4? and
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CD8? T lymphocytes, as well as by inhibiting the activity
of immunosuppressive Treg or myeloid-derived suppressor
cells (MDSC) (Szala et al. 2010). This causes polarization
of the tumor microenvironment from a proangiogenic and
immunosuppressive towards an antiangiogenic and im-
munostimulatory one (Ciomber et al. 2014; Huang et al.
2013; Jarosz et al. 2013; Ostrand-Rosenberg 2008).
The aim of our study was the elaboration of an anti-
cancer therapeutic strategy based on induction of immune
response which leads to polarization of tumor milieu. In
our study, we investigated the effect of a tumor cell-based
vaccine combined with murine interleukin (IL)-12 on
immune response and polarization of the tumor microen-
vironment. The vaccine was constructed in our laboratory
from B16-F10 melanoma cell cultures treated with
CAMEL peptide. CAMEL, abbreviated as
CA(1–7)M(2–9), consists of two fragments. One is derived
from cecropin A [amino acids CA(1–7)], a peptide occur-
ring in Hyalophora cecropia hemolymph, and the other
from melittin [amino acids M(2-9)], a peptide from Apis
mellifera (honeybee) (Smolarczyk et al. 2010). CAMEL
peptide is capable of penetrating the cell membrane with-
out damaging it. Following cell penetration, CAMEL
localizes in mitochondria, inducing their swelling and
consecutive disruption. The disruption of the mitochondrial
membrane leads to a decrease in intracellular ATP level, as
well as the release of HMGB1 (high-mobility group box 1
protein), triggering necrotic cell death (Smolarczyk et al.
2010). This peptide has not been used before as a tool to
construct vaccines; however, in our previous studies, we
showed that after intratumoral administration, CAMEL
inhibited the growth of B16-F10 tumors (Smolarczyk et al.
2010, 2012). In this study, we used CAMEL as a cell
necrosis-inducing agent. The lysates next served as a
vaccine to induce an anticancer immune response. IL-12,
as used in our study, was meant to further enhance the
immune response. IL-12 was administered to animals in the
form of gene therapy, and was mediated by plasmid DNA
(Budryk et al. 2000; Ciomber et al. 2014; Jarosz et al.
2013). IL-12 is a pleiotropic immunomodulatory cytokine
with antiangiogenic activity (Del Vecchio et al. 2007;
Kilinc et al. 2006; Uemura et al. 2010). IL-12 increases the
synthesis of interferon (IFN)-c by NK and T cells, stimu-
lates the growth and cytotoxicity of activated NK, CD8?
and CD4? T cells, induces differentiation of CD4? Th0
cells into Th1 phenotype, enhances antibody-dependent
cell cytotoxicity against cancer cells, and induces IgG an-
tibodies and inhibits the synthesis of IgE antibodies by B
lymphocytes (Lasek et al. 2014). Additionally, IL-12
eliminates Treg lymphocytes from the tumor microenvi-
ronment, effectively abrogating tumor immunosuppression
(Kilinc et al. 2006). IL-12 inhibits the formation of new
blood vessels by stimulating antiangiogenic cytokines and
chemokines. IL-12 also causes remodeling of the peritu-
moral extracellular matrix and tumor stroma,
reprogramming of suppressor myeloid cells, and stimulates
the overexpression of MHC class I molecules. All the
above mechanisms are postulated to be responsible for the
high potency of anti-tumor effects of IL-12 (Lasek et al.
2014).
In this work, we intended to investigate the effect of
combination therapy on the tumor microenvironment. Our
results suggest that this tumor cell-based vaccine, together
with IL-12, induces immune response and polarizes the
tumor microenvironment towards an antiangiogenic/anti-
vascular and immunostimulatory one. Tumor milieu
polarized in such a manner inhibits the growth of B16-F10
murine melanoma tumors in treated animals. It seems that
the combination of tumor cell-based vaccine with IL-12 is
a promising therapeutic approach that can be employed as
one of the arms of multimodal anticancer strategies.
Materials and Methods
Mice, Plasmid, Drug and Cell Line
Mice (6- to 8-week-old, C57Bl/6NCrl females) were bred
in our animal facility house. The experimental protocol
was approved by the Local Ethics Commission (Medical
University of Silesia, Katowice, Poland). Tumor growth
inhibition was monitored using a murine B16-F10 me-
lanoma model. Growing tumors were measured with
calipers, and tumor volumes were determined using the
formula: volume = width2 9 length 9 0.52. Plasmid
pBCMGSNeo carrying a gene encoding murine IL-12 was
obtained from Prof. H. Yamamoto (Osaka University, Ja-
pan). Plasmid preparations were isolated using a QIAGEN-
Endo Free Giga Kit (QIAGEN GmbH, Hilden, Germany).
CAMEL (KWKLFKKIGAVLKVL-NH2) and fluorescein
isothiocyanate (FITC)-conjugated CAMEL were synthe-
sized by Prof. W. Kamysz (Gdansk Medical University,
Poland) using 9-fluorenylmethoxycarbonyl solid-phase
chemistry. The purity of the synthesized peptide (95–97 %)
was verified by reversed-phase HPLC. The physicochem-
ical properties of CAMEL were further analyzed using
matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry (Smolarczyk et al.
2010). B16-F10 (murine melanoma) cell line (ATCC,
Manassas, VA, USA) was maintained using RPMI 1640
medium (Gibco BRL, Paisley, UK) supplemented with
10 % fetal bovine serum (ICN Biomedicals, Costa Mesa,
CA, USA). Cell cultures were kept under standard condi-
tions (37 C, 5 % CO2, 95 % humidity). B16-F10
(1.8 9 105 CAMEL-treated cells and 3 9 104 control
cells) was used as in Casares et al. (2005).
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Tumor Cell Lysate Preparation
To generate a tumor cell-based vaccine, B16-F10 cells
were treated with CAMEL peptide. Four doses (5, 10, 20
and 40 lM) of the peptide were checked. After 24 h the
cells were stained with annexin V and 7-AAD and ana-
lyzed by flow cytometry (BD FACSAriaTM III; BD,
Franklin Lakes, NJ, USA). A 40 lM concentration of
CAMEL was proven effective in killing over 97 % of cells.
After washing twice with phosphate-buffered saline
(PBS)-, the aliquots of 100 lL PBS- containing lysate
from 1.8 9 105 CAMEL-treated tumor cells were used per
animal. Vaccine samples were stored at -80 C until use.
Detection of Necrosis In Vitro
Necrosis of B16-F10 cells was determined using an An-
nexin V-PE Apoptosis Detection Kit (BD Pharmingen, San
Diego, California, USA). Twenty-four hours after admin-
istering CAMEL detached B16-F10 murine melanoma
cells (4 9 105) were twice rinsed with PBS- and resus-
pended in 1 mL of binding buffer. The staining procedure
followed kit instructions. Analysis of labeled cells’
fluorescence was performed using an FACSAriaTM III flow
cytometer (BD). Additionally, B16-F10 cells (2 9 105)
were treated with FITC-conjugated CAMEL (40 lM),
following which propidium iodide (PI; 0.5 mg/mL) was
added. Images were taken using a Zeiss Cell Observer SD
Semiconfocal Microscope (Carl Zeiss, Jena, Germany).
Lens magnifications were 209 and 639.
Tumor Cell Challenge, Treatment
with Immunomodulatory Factors
Seven days after inoculating the mice (lower flank) with
B16-F10 melanoma cells (3 9 104/100 lL PBS-), subcu-
taneous injections (contralateral flank) of CAMEL-treated
tumor cell vaccine (1.8 9 105/100 lL PBS-) were initi-
ated. Tumor cell-based vaccine was administered three
times, 1 week apart. Additionally, in the combined therapy
regimen, 24 h following the administration of each tumor
cell-based vaccine, plasmid DNA encoding IL-12 gene was
injected at the same spot [50 lg/100 lL PBS- pH 7.4
(Budryk et al. 2000; Mitrus et al. 2006)].
Flow Cytometric Analysis
Mice were killed on the 28th day of the experiment. Left
and right cervical lymph nodes (LNs) were isolated. LN
cells were counted and single-cell suspension was used for
flow cytometric analysis. Following live cell gating, the
percentage of CD4? and CD8? T lymphocytes was de-
termined. Also, tumor material was collected for flow
cytometric analysis; single-cell suspension was obtained
using a digestion mix (0.5 mg/mL collagenase A, Sigma
Aldrich; 0.2 mg/mL hyaluronidase type V, Sigma Aldrich;
0.02 mg/mL DNase I, Roche; per 0.25 g of tumor tissue).
Red blood cells were lysed using 0.15 M ammonium
chloride (Sigma Aldrich, St Louis, MO, USA). Dead cells
were removed by centrifugation using Lympholyte-M
gradients (Cedarlane, Ontario, Canada). To identify the
subpopulations of T lymphocytes, the following antibodies
were used: PE-Cy7-CD3e, PE-CD4 and FITC-CD8a (BD
Pharmingen). Treg lymphocytes were identified with
FITC-CD4, APC-CD25 and PE-Foxp3 antibodies (eBio-
sciences; San Diego, CA, USA). Finally, to identify the
level of NK cells, an anti-mouse CD49b (pan-NK cells)
antibody was used (eBioscences). In flow cytometric ana-
lyses (BD FACSCanto, BD), gate dividing negative from
positive cells was based on isotype antibody control probes
(Jarosz et al. 2013).
Immunohistochemistry
Mice were killed on the 28th day of the experiment. Tu-
mors were excised to identify tumor vessels; paraffin
sections (5 lm) were stained immunohistochemically:
following overnight incubation (4 C) with rabbit anti-
CD31 polyclonal primary antibody (Abcam, Cambridge,
UK), the sections were incubated (45 min/room tem-
perature) with FITC-conjugated secondary antibody
(Vector Laboratories, Burlingame, CA, USA) and cover
slipped with Vectashield mounting medium containing
DAPI (Vector Laboratories). Images were taken using a
Zeiss LSM 710 confocal microscope (Carl Zeiss). The
numbers of blood vessels in each group were determined
based on 10 visual field counts from four tumor sections
(lens magnification: 209).
Statistical Analysis
The statistical significance of differences between the ex-
perimental and control groups were evaluated by the
analysis of variance test (ANOVA). P values\0.05 were
considered statistically significant.
Results
CAMEL Peptide Induces Necrosis
Tumor cell-based vaccine was prepared following me-
lanoma cell cultures’ treatment with CAMEL peptide. To
achieve this, CAMEL concentration resulting more than
95 % of B16-F10 cells’ death was determined. Four dif-
ferent peptide doses (5, 10, 20 and 40 lM) were examined.
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Quantification of apoptotic/necrotic cells was performed by
flow cytometry and PE-annexin V, as well as 7-AAD
staining.
We confirmed that CAMEL localizes inside B16-F10
murine melanoma cells and causes necrotic cell death. The
peptide (FITC-CAMEL staining) does not cause the de-
struction of cell membranes (lack of red PI staining of cell
nucleus) and localizes in the cytoplasm. With time, the
accumulation of CAMEL in cells causes cell swelling and
rupture of the plasma membrane triggering cell death (red
PI staining of cell nucleus) [Fig. 1a; (Smolarczyk et al.
2010)]. Above 97 % of the cells underwent necrosis (an-
nexin V?7-AAD?) as a result of the treatment with 40 lM
CAMEL concentration (Fig. 1b). Accordingly, tumor cell-
based vaccine was prepared from B16-F10 cell lysates
following cells’ treatment with 40 lM CAMEL.
Combination of Tumor Cell-Based Vaccine
and IL-12 Effectively Inhibits Tumor Growth
Next, we examined the therapeutic effect of our tumor cell-
based vaccine and its combination with gene therapy me-
diated by plasmid DNA construct encoding murine IL-12.
For this purpose, mice were first inoculated with B16-F10
cells (right flank) and, after 7 days, the tumor cell-based
vaccines were administered subcutaneously (left flank)
three times, 1 week apart (Fig. 2a, b). Each vaccine ad-
ministration was followed 24 h later by gene therapy
(injection in the same spot).
We noted that our tumor cell-based vaccine inhibits the
growth of B16-F10 murine melanoma, compared to control
(PBS-). However, significant inhibitory results were ob-
tained using a combination of the vaccine with IL-12
(85 % inhibition of tumor growth) rather than using either
of the agents alone (59 % inhibition following vaccine
administration and 51 % inhibition in the case of gene
therapy, see Fig. 2c, d). Comparing tumor-derived histo-
chemical specimens from mice treated with the
combination regimen and those from the control, we noted
decreased number of tumor blood vessels, more extensive
necrotic areas and enhanced infiltration of immune cells in
tumor sections in the case of combined therapy (Fig. 2e).
Tumor Cell-Based Vaccine in Combination
with IL-12 Induces Immune Response
We examined the effect of tumor cell-based vaccine as
well as IL-12 on immune response. One week after
inoculating mice with cancer cells, the therapy was initi-
ated with vaccine administration (on days 7, 14 and 21),
followed by IL-12-mediated gene therapy (days 8, 15 and
22). One week after the last drug injection, mice were
killed and cervical lymph nodes as well as tumors were
collected. The levels of T lymphocytes and NK cells were
determined by flow cytometry.
The combinatory therapeutic regimen used resulted in
the induction of both nonspecific and specific immune
responses. This consisted of increased infiltration of
CD4? and CD8? T lymphocytes in cervical lymph nodes
of the treated mice (Fig. 3a). Also, a threefold increase
of tumor-infiltrating CD4? T cells and a twofold increase
of CD8? T cells, respectively, were observed as com-
pared to monotherapy. CD4? T cells play a central role
in regulating all antigen-specific immune responses, and
a role in both the induction and the effector phases of
the anti-tumor response. CD8? T cells can induce the
cytolytic death of target tumor cells or promote tumor
destruction via the secretion of effector cytokines such as
IFN-c or tumor necrosis factor (TNF)-a (Savage et al.
2014). In addition, we noted an increased expression
level of CD49b, an NK cell marker, in tumors of the
treated mice as compared to controls (twofold and
threefold increase with respect to monotherapies and
sixfold increase compared to control (PBS-), Fig. 3b).
Natural killer (NK) cells are effector lymphocytes of
innate immunity and provide a crucial contribution in
tumor immunosurveillance (Waldhauer and Steinle
2008).
Combination Therapy (Tumor Cell-Based
Vaccine 1 IL-12) Decreases the Number of Tumor
Blood Vessels and the Level of Tumor Treg
Lymphocytes
After revealing an induced immune response following
combination therapy, we examined its effect on the number
of tumor blood vessels, as well as the level of tumor
regulatory T lymphocytes. One week after the cessation of
therapy tumor material was excised for immunohisto-
chemical analysis. The staining was performed using an
antibody directed against a marker of endothelial cells,
CD31, as well as for cytofluorimetric assessment of
the level of tumor-infiltrating Treg lymphocytes
(CD4?CD25high?Foxp3?).
Immunohistochemical analyses demonstrated a sig-
nificant reduction in the number of blood vessels in tumor
specimens from mice treated with tumor cell-based vaccine
combined with IL-12 (Fig. 4), when compared to controls
(1.5-fold decrease with respect to monotherapies and
twofold decrease compared to PBS-). Blood vessels play
an important role in tumor progression. Solid tumors larger
than 1–2 mm3 require their own vascular system for further
progression (Folkman 1971; Tabi and Man 2006). Angio-
genesis enables the supply of oxygen and growth factors to
tumor cells and their microenvironment, and the removal
of metabolites (Baeriswyl and Christofori 2009).
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Cytofluorimetric analyses showed that monotherapies
markedly decreased the level of tumor Treg lymphocytes.
However, compared to the control (mice receiving PBS-)
and monotherapies, more than threefold and twofold de-
crease was observed for Tregs level in tumors from mice
treated with combination therapy. Regulatory T cells
Fig. 1 Tumor cell-based vaccine construction. Induction of necrosis
by CAMEL. a B16-F10 cells were treated with FITC-CAMEL, and
then propidium iodide (PI) was added. Lens magnification: 920 and
963. The peptide (green fluorescence) localizes in the cytoplasm.
With time, the accumulation of CAMEL in cells causes cell swelling
and rupture of the plasma membrane, triggering cell death (red
fluorescence). b B16-F10 cells treated with CAMEL (5–40 lM).
Twenty-four hours later cells were stained with annexin V and
7-AAD and analyzed by flow cytometry. After treatment with 40 lM
CAMEL[97 % cells were necrotic (annexin V?7-AAD?)
Arch. Immunol. Ther. Exp. (2015) 63:451–464 455
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(Tregs) inhibit a cytotoxic immune reaction and promote
tumor cell growth, angiogenesis and metastasis (Gutkin
and Shurin 2014). Accumulation of Tregs in the tumor
microenvironment shifts the balance between effector and
suppressor lymphocytes, and induces an immunosuppres-
sive state (Rabinovich et al. 2007; Zou 2005). Abrogation
of the immunosuppressive state may be associated with the
decreased number of Treg cells. This clearly underscores
the benefit of a combined therapeutic approach in dimin-
ishing immunosuppression in the tumor microenvironment
(Fig. 5).
Our results show that the tumor cell-based vaccine,
when used in combination with IL-12 gene therapy, does
induce immune response and changes/polarizes the tumor
microenvironment from a proangiogenic/immunosuppres-
sive towards an antiangiogenic/immunostimulatory one
(Fig. 6).
Discussion
New therapeutic approaches engage the immunotherapy
for cancer treatment (Russo et al. 2014). Tumor im-
munotherapy aims at restoring the ability to eliminate
neoplastic cells through the body’s defense mechanisms
(Kozłowska et al. 2013; Mocellin et al. 2004a, b). In
clinical studies on advanced melanoma monoclonal anti-
bodies are used. First drug approved by the US Food and
Drug Administration was ipilimumab that binds CTLA-4
and blocks the interaction of CTLA-4 with its ligands,
CD80 and CD86. Ipilimumab acts via indirect mechanism
induced by T lymphocytes in anti-tumor immune response.
On the other hand, vemurafenib and dabrafenib inhibit
mutations of BRAF V600, which prevents oncogenic ac-
tivities such as proliferation and evasion of immune
response (Olszanski 2014; Russo et al. 2014). A promising
alternative is vaccination using whole tumor cells (Chiang
et al. 2010). Immunotherapy may be involved in the
treatment because tumor cells express tumor-associated
antigens, for example, MART1, gp100 and tyrosinase in
melanoma (Russo et al. 2014). Vaccines may contain live
or dead cancer cells (Kozłowska et al. 2013; Menaria et al.
2013). Whole tumor cells and their lysates contain an entire
panel of antigens that can be recognized by DCs, thus
markedly increasing the chances of successful therapeutic
outcome (Ward et al. 2002). Live cancer cells are weakly
immunogenic and release immunosuppressants which
block the maturation of DCs [e.g., vascular endothelial
growth factor (Peter et al. 2008), transforming growth
factor b (Flavell et al. 2010)] or lead to apoptosis of T
lymphocytes (Chiang et al. 2010; Ohm et al. 2003). The
remnants of dead cancer cells, on the other hand, trigger an
immune response. Whole tumor cells as a rich source of
antigens expresses the epitopes for CD8? cytotoxic T cells
and CD4? T helper (Th) cells. Parallel presentation of
antigens both in the context of MHC class I and II mole-
cules contributes to the stronger overall anti-tumor
response and long-term immunological memory of CD8?
T cells via CD4? Th cells (Chiang et al. 2010). Necrotic
cells are phagocytosed by immature DCs, causing the
maturation of the latter (Basu et al. 2000; Sauter et al.
2000). This is important insofar as immature DCs stimulate
tumor angiogenesis (Ma et al. 2013). Vaccines offer ad-
vantages such as low cost, and ease of preparation and
storage. They can be administered in a site different from
tumor location, so they are useful in treating hard-to-reach
malignancies, micrometastases or residual disease. To sum
up, tumor cell-based vaccines appear to be a promising tool
to induce anti-tumor immune response.
As opposed to the established efficacy of prophylactic
vaccines used in treating infectious diseases, the
therapeutic effects of anticancer vaccines have remained
low in general (Escors 2014). The failure results from the
presence of numerous factors supporting tumor growth and
escape from immune surveillance (Tabi and Man 2006;
Terando et al. 2007). Such factors include uncontrolled
proliferation, presence of tumor necrosis and heteroge-
neous tumor vascular network, release of
immunosuppressive cytokines, downregulation of MHC
class I molecules, as well as a loss of antigens by cancer
cells (Terando et al. 2007). A primary goal of cancer im-
munotherapy is to elicit CD8? T cells that are able to
detect tumor-expressed antigen with high specificity and
sensitivity, while limiting damage to normal cells. More-
over, due to Tregs’ potent immunosuppressive function,
many emerging strategies aim to augment effector T cell
response by the depletion or blockade of Treg lymphocytes
in tumors (Savage et al. 2014).
To break immune tolerance, administration of tumor
antigens is often combined with the application of
bFig. 2 Inhibition of B16-F10 tumor growth in response to combina-
tion therapy involving tumor cell-based vaccine and IL-12. a, b Seven
days after inoculation (lower flank) with B16-F10 melanoma cells
(3 9 104/100 lL PBS-; n = 9) subcutaneous injections of lysate
from CAMEL-treated tumor cells (1.8 9 105/100 lL PBS-) were
started (contralateral flank). The vaccine was administered three
times, 1 week apart. In combined therapy regimen, 24 h after each
vaccine administration plasmid DNA encoding IL-12 gene was
additionally injected at the same site (50 lg/100 lL PBS-). c Com-
bined therapy was highly effective in inhibiting tumor growth
compared to controls receiving single-agent therapy. Compared to
control, statistical differences on the 25th day of therapy were
*P \ 0.01, **P\ 0.05. d Photographs taken on the 28th day of the
experiment. e Tumors (n = 3) were collected 4 weeks after challenge
and counterstained with hematoxylin/eosin. Considerable necrotic
areas (red arrows) and immune cell infiltration (blue) seen in tumor
sections from mice treated with tumor cell-based vaccine, IL-12, or
their combination. Magnification: 920
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immunostimulatory agents (Terando et al. 2007). Enhanced
immune response can be obtained using vaccines with
various adjuvants. The majority of them are directed at
antigen-presenting cells, and they enhance induction of
strong cellular immune response by Th1 cells and induc-
tion of specific cytotoxic T lymphocytes directed against
tumor antigens (Muehlbauer and Schwartzentruber 2003).
An example is IL-12, a pleiotropic cytokine inducing a
nonspecific (NK, NK-T cells) or specific (CD4? and CD8?
T cells) immune responses, as well as showing strong an-
tiangiogenic properties (Del Vecchio et al. 2007; Kilinc
et al. 2006; Uemura et al. 2010; Weiss et al. 2007). IL-12
was widely used in preclinical studies, but produced poor
outcomes when administered in the form of recombinant
protein during clinical studies (Lasek et al. 2014). In our
research, we used IL-12 for gene therapy to enhance im-
mune response induced by cell-based vaccine, and analyze
the effects of this combination on the polarization of the
tumor microenvironment. IL-12 enhances the infiltration of
tumor mass by T lymphocytes, macrophages and NK cells
(Dickerson et al. 2004). IL-12 also affects the expression of
adhesion molecules which take part in directing DCs
Fig. 3 Induction of immune response by treatment with tumor cell-
based vaccine and IL-12. One week after final drug injection, mice
(n = 8) were killed. Cervical lymph nodes and tumor material were
collected for flow cytometric analysis to determine the levels of T
lymphocytes and NK cells. a Higher level of T cells in draining
lymph nodes were noted in the case of combined therapy. Compared
to controls, statistical differences were *P\ 0.05, **P\ 0.0025,
***P\ 0.0005. b Significantly higher levels of tumor-infiltrating
CD4?, CD8? T cells and NK cells were found after combined
therapy. Compared to controls, statistical differences were
*P\ 0.025, **P\ 0.035, ***P\ 0.02
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towards the tumor mass. IL-12 triggers the activation and
maturation of DCs (Kim et al. 2006). In addition, IL-12
eliminates regulatory T lymphocytes from the tumor
microenvironment, effectively abrogating tumor immuno-
suppression (Kilinc et al. 2006).
We intended to verify the effectiveness of a tumor cell-
based vaccine in combination with IL-12 in inhibiting tu-
mor growth in an experimental murine melanoma model,
as well as to study the impact of this combination on the
polarization of the tumor microenvironment. There have
been conflicting reports concerning the therapeutic benefit
of using UV-irradiated cells. Some investigators observed
the induction of immunogenic cell death in neoplastic cells
(e.g., Obeid et al. 2007), whereas others did not notice such
an effect (Fucikova et al. 2011). In our study, we used
CAMEL peptide to induce cancer cell death. CAMEL
peptide causes mitochondrial swelling and disrupts the
mitochondrial membrane, leading to a decrease in intra-
cellular ATP levels, and thus triggering necrotic cell death.
Dead tumor cells release alarmins and induce a strong
immune response (Chiang et al. 2010). CAMEL-treated
tumor cells release factors such as HMGB1 (Smolarczyk
Fig. 4 Reduced number of
tumor blood vessels following
combined therapy. One week
after the last drug injection mice
were killed, and tumors excised,
fixed and stained with antibody
against CD31 (marker of
endothelial cells, green
fluorescence). The number of
vessels was counted for each
experimental group in ten visual
fields from four tumor sections
(magnification: 920).
Significantly decreased numbers
of vessels were found in tumor
sections from mice treated with
combined therapy as compared
to controls. Compared to
control, the statistical difference
was *P\ 0.0001
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et al. 2010). The release of HMGB1 protein causes the
inflammation because of the influx of lymphocytes, mac-
rophages, neutrophils and mast cells, activation of defense
mechanisms and repair of the affected tissue (Smolarczyk
et al. 2010). Furthermore, HMGB1 released during necrotic
cell death interacts with Toll-like receptor (TLR)4 on DCs
and stimulates the processing and presentation of tumor-
derived antigens. TLR4 binds HMGB1 what prevents tu-
mor antigens digestion and facilitates their trafficking to
the dedicated antigen-presenting compartment (Chiang
et al. 2010). In previous studies, we used CAMEL peptide
injected directly into the tumor. This peptide penetrated
into cancer cells and caused their necrosis (Smolarczyk
et al. 2010). However, cancer cells account only for 30 %
of all cells in the tumor (Becker et al. 2013). Therefore,
modern therapy has to be targeted at the tumor microen-
vironment formed by the extracellular matrix, immune
cells and tumor blood vessels. In this study, we used
CAMEL peptide to design a cell-based vaccine which was
then administered to induce an anti-tumor immune re-
sponse. The purpose of the combination of the cell-based
vaccine with IL-12 was to enhance this response and re-
duce the number of tumor blood vessels necessary for
tumor progression.
To this goal, mice were challenged with live B16-F10
melanoma cells and, starting 7 days later, tumor cell-based
Fig. 5 Reduced level of Treg
lymphocytes after combined
therapy. On the 28th day of the
experiment, tumors (n = 8)
were excised. Single-cell
suspensions obtained were then
used to quantitate Treg
lymphocyte levels. The
percentage of
Foxp3?CD25high? regulatory
lymphocytes (subpopulation of
CD4? T lymphocytes) was
determined from the
lymphocyte population gate.
The largest decrease in the level
of tumor Treg lymphocytes was
found for the group of mice
treated with combined therapy.
Compared to controls, the
statistical difference was
*P\ 0.03
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vaccine was administered contralaterally at weekly inter-
vals (a total of three times). Twenty-four hours after each
vaccine administration, pBCMGSNeo/IL-12 plasmid was
injected at the same spot. We observed that the vaccine
together with IL-12 yielded better tumor inhibitory effects
compared to either agent alone. Post-therapeutic analysis
showed decreased numbers of tumor blood vessels, con-
siderable necrotic areas, and increased immune cell
infiltration in tumor sections from mice treated with the
combination regimen. We observed, however, no complete
cures following the proposed combination therapy. The
decreased effectiveness of our tumor cell-based vaccine
may be the result of an existing time span between vaccine
effects (treatment initiation), i.e., the appearance of anti-
tumor immune effector cells, and the continuing prolif-
eration of cancer cells (Terando et al. 2007). Murine
melanoma is a very fast-growing tumor. Immunotherapies
require time to maximize their anti-tumor activity, leading
to durable response and long disease-stable or disease-free
intervals (Olszanski 2014). Additionally, multiple necrotic
areas and an abnormal tumor vascular network both limit
the contact of tumor-specific cytotoxic T lymphocytes with
viable tumor cells (Terando et al. 2007). Also, it ought to
be remembered that IL-12-mediated gene therapy was
administered (contralaterally) into a non-tumor site. This
might weaken the effectiveness of IL-12 treatment (Oshi-
kawa et al. 2001). Intratumoral administration results in
increased concentration of IL-12 at the site of endothelial
cells’ proliferation, which considerably enhances its an-
tiangiogenic and antineoplastic activity (Dickerson et al.
2004).
Therapy based solely on the use of antiangiogenic fac-
tors is not sufficient to inhibit the tumor mass growth.
Clinical data show a number of limitations of such therapy:
adverse effects, toxicity, acquired drug resistance and ag-
gressive recurrence of tumors after withdrawal of
antiangiogenic treatment (Gacche and Meshram 2014).
Antiangiogenic therapy is not effective in eliminating the
tumor blood vessels arisen in the process of co-option of
preexisting normal vessels or vascular mimicry in which
neoplastic cells can directly form vessel walls (Moserle
et al. 2014). Furthermore, due to antiangiogenic drug-in-
duced therapy, the hypoxia arises. Hypoxia is a major
cause of cancer cell invasiveness and metastasis (Azam
et al. 2010; Ebos et al. 2009; Keunen et al. 2011; Pa`ez-
Ribes et al. 2009). However, the antiangiogenic therapy has
the advantages that may be used in designing combined
therapy with cell vaccines. Angiogenic inhibitors have
Fig. 6 Polarization of tumor microenvironment by tumor cell-based
vaccine and IL-12. Tumor progression depends on tumor milieu,
which influences neovasculature formation and immunosuppression
(allowing cancer cells’ escape from immune surveillance) (Hanahan
and Coussens 2012; Szala et al. 2010). Combining immunotherapy
with antiangiogenic therapy might be an effective therapeutic
approach (Huang et al. 2013; Tartour et al. 2011). The combination
tested seems to polarize the tumor microenvironment, resulting in a
switch from a proangiogenic/immunosuppressive to an antiangio-
genic/immunostimulatory one. The switch appears as a decreased
number of tumor blood vessels, increased levels of CD4?, CD8? T
cells and NK cells, as well as lower levels of suppressor lymphocytes
(Tregs) in tumors of treated mice. Ultimately, this results in tumor
growth arrest
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potential anti-tumor activity via re-establishing Treg con-
centration to a physiological level avoiding autoimmune-
mediated side effects, and they do not eliminate activated T
cells but inhibit MDSC; they also enhance Th1 response
after mitogenic restimulation, and increase the level of
tumor-infiltrating T cells. Therefore, antiangiogenic
strategies inhibiting tumor-induced immunosuppressive
mechanisms create permissive conditions to induce an ef-
ficient anti-tumor immune response after vaccination
(Terme et al. 2012).
As did Wu et al. (2007), we noted increased levels of T
lymphocytes in the cervical lymph nodes of mice treated
with the combination therapy, as compared to mono-
therapies. In this case, we also noted the distinct activation
of both nonspecific and specific immune responses. The
activation manifests itself as the enhanced infiltration of
cells such as CD4? and CD8? T lymphocytes, as well as
NK cells, and also as decreased levels of regulatory T
lymphocytes in tumors from treated mice. Several studies
found a favorable prognostic effect of concurrent infiltra-
tion by CD4? and CD8? T cells, as well as NK cell density
at the tumor mass (Gutkin and Shurin 2014). NK cells
stimulate the maturation of DCs and facilitate adaptive
anti-tumor immunity. Indeed, NK cells link innate immu-
nity and adaptive immunity (Zou 2005). NK cells play the
key role in the elimination of cancer cells which have lost
the ability of MHC expression (Gutkin and Shurin 2014)
through the engagement of their activating receptors and
the lack of engagement of their inhibitory receptors (Os-
trand-Rosenberg 2008). Cytotoxic T lymphocytes (CD8?)
kill cancer cells after identification of cancer antigens in
the context of MHC class I molecules. CD8? T lympho-
cytes are able to induce the death of cancer cells by
cytolytic activity or secretion of effector cytokines such as
IFN-c or TNF-a (Savage et al. 2014). On the other hand,
CD4? T lymphocytes form a large fraction of tumor-in-
filtrating lymphocytes and play an important role in the
immune surveillance of the tumor. They are involved in
both the induction and effector phase of the anti-tumor
immune response (Protti et al. 2014). Two major sub-
populations of CD4? T lymphocytes (i.e. Th1 and Th2) are
found in tumors. CD4? Th1 lymphocytes elicit anti-tumor
activity, both directly by killing cancer cells after identi-
fication of cancer antigens in the context of MHC class I
molecules and by releasing cytolytic molecules, and indi-
rectly by activating cytokine release from macrophages.
CD4? Th2 lymphocytes elicit anti-tumor activity by re-
leasing IL-5 and activation of eosinophils with tumoricidal
properties (Protti et al. 2014). The high percentage of Treg
cells in various tumors creates the immune suppressive
microenvironment that restrains anti-tumor immunity, thus
promoting tumor growth (Gutkin and Shurin 2014).
Regulatory T cells inhibit the proliferation of CD8? T
lymphocytes and the maturation of DCs, and promote tu-
mor angiogenesis (Facciabene et al. 2012; Ostrand-
Rosenberg 2008). The accumulation of Treg lymphocytes
in tumors is one of the causes of immunosuppressive
conditions occurrence (Zou 2005) and the shift in equi-
librium between effector and suppressor T cells
(Rabinovich et al. 2007; Zou 2005). A decrease in Tregs
levels indicates abrogation of the immunosuppressive state
in tumors. Reversion (polarization) of the tumor microen-
vironment by such a drug combination, i.e., stimulation of
the immune system to recognize neoplastic cells as foreign,
as well as elimination of tumor blood vessels, leads to the
arrest of tumor growth (Ciomber et al. 2014; Huang et al.
2012; Jarosz et al. 2013). It seems that the results reported
herein implicate such a conversion of tumor milieu.
To summarize, the combination of CAMEL-treated tu-
mor cell-based vaccine and IL-12 does inhibit the growth
of B16-F10 murine melanoma experimental tumors. The
obtained therapeutic effect is likely caused by tumor mi-
croenvironment polarization, which stimulates the immune
response and abrogates immunosuppression, and also in-
hibits the formation of tumor blood vessels. We suppose
that combinations of immunomodulation with antiangio-
genic agents represent a promising therapeutic approach,
useful as a complement to conventional modalities of tu-
mor treatment.
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